Faculty

Rolf P. Kreutz, MD

Associate Professor of Clinical Medicine

Address

Methodist Hospital, Room KIC E400
1701 Senate Blvd.

Indianapolis, IN 46202-1239

Bio

Dr. Kreutz is an Associate Professor of Clinical Medicine at the Indiana University School of Medicine and Interventional Cardiologist in the Division of Cardiovascular Medicine. Dr. Kreutz is Chief of Cardiology and Medical Director of the cardiac catheterization laboratories at Eskenazi Health and Associate Program Director for the Interventional Cardiology Fellowship at Indiana University.

Dr. Kreutz received his medical degree from the University of Bern in Switzerland. He completed his residency training at the Johns Hopkins University/Sinai Program in Internal Medicine and subspecialty training in cardiovascular disease and interventional cardiology at Indiana University School of Medicine.

Dr. Kreutz is a member of the multidisciplinary structural heart team at IUH Methodist. His research interests include personalized medicine, pharmacogenetics, thrombosis, and therapies for coronary artery disease.

Titles & Appointments

Associate Professor of Clinical Medicine
Eskenazi Cardiology Medical Director
Associate Program Director for Research - Interventional Cardiology Fellowship

Education

2010 FEL Interventional Cardiology Fellowship, Indiana University School of Medicine

2009 FEL Cardiology Fellowship, Indiana University School of Medicine

2006 RES Internal Medicine Residency, Hospital of Langenthal, Switzerland<br />University Hospital of Zurich, Switzerland<br />Johns Hopkins University/Sinai, Baltimore

1999 MD University of Bern
Research

My research interests are translational in nature, and focus on thrombosis, coronary artery disease, antiplatelet medications and ‘personalized medicine’. I am studying the effect of variations in the human genome on in- vivo drug response through pharmacogenetic analyses. I am interested in the effects of genomic or epigenetic variations on coronary thrombosis phenotypes, and use of ex-vivo thrombosis assays in risk stratification of patients with coronary artery disease.
Publications

Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y(12) Inhibitor Prescribing After Percutaneous Coronary Intervention.
Cavallari LH; Limdi NA; Beitelshees AL; Lee JC; Duarte JD; Franchi F; Tuteja S; Giri J; Empey PE; Kreutz RP; Skaar TC; Allen JM; Coons JC; Gong Y; McDonough CW; Stevenson JM; Thomas CD; Johnson JA; Stouffer GA; Angiolillo DJ; Lee ACR; IGNITE Network; Clinical pharmacology and therapeutics 2022 Oct 28

Isolated Right Ventricular Myocardial Infarction Presenting With Anterior ST-Segment Elevation.
Mallory R; Kreutz RP; JACC. Case reports 2022 May 4

MicroRNA sequencing in patients with coronary artery disease - considerations for use as biomarker for thrombotic risk.
Onuoha CP; Ipe J; Simpson E; Liu Y; Skaar TC; Kreutz RP; Clinical and translational science 2022 May 29

Social deprivation index and ischemic events after percutaneous coronary intervention in patients with diabetes mellitus.
Torabi AJ; Mshelbwala FS; Hugenberg D; Kovacs RJ; Kreutz RP; Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2022 Jan 30

<i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.
Beitelshees AL; Thomas CD; Empey PE; Stouffer GA; Angiolillo DJ; Franchi F; Tuteja S; Limdi NA; Lee JC; Duarte JD; Kreutz RP; Skaar TC; Coons JC; Giri J; McDonough CW; Rowland R; Stevenson JM; Thai T; Vesely MR; Wellen JT; Johnson JA; Winterstein AG; Cavallari LH; Lee CR; Implementing Genomics in Practice (IGNITE) Network Pharmacogenetics Working Group.; Journal of the American Heart Association 2022 Feb 12

Antithrombotic Strategy After Transcatheter Aortic Valve Replacement: A Network Meta-Analysis.
Mahalwar G; Kumar A; Majmundar M; Adebolu O; Yendamuri R; Lao N; Barve N; Kreutz RP; Reed GW; Puri R; Dani SS; Kalra A; Current problems in cardiology 2022 Aug 6

Early Pregnancy Atherogenic Profile in a First Pregnancy and Hypertension Risk 2 to 7 Years After Delivery.
Catov JM; McNeil RB; Marsh DJ; Mercer BM; Bairey Merz CN; Parker CB; Pemberton VL; Saade GR; Chen YI; Chung JH; Ehrenthal DB; Grobman WA; Haas DM; Parry S; Polito L; Reddy UM; Silver RM; Simhan HN; Wapner RJ; Kominiarek M; Kreutz R; Levine LD; Greenland P; NHLBI nuMoM2b Heart Health Study.; Journal of the American Heart Association 2021 Feb 23

Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH; IGNITE Network Pharmacogenetics Working Group.; Clinical pharmacology and therapeutics 2020 Sep 8

Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations.
Chaudhary R; Bliden KP; Kreutz RP; Jeong YH; Tantry US; Levy JH; Gurbel PA; EClinicalMedicine 2020 Nov 20

Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019.
Maatman TK; Jalali F; Feizpour C; Douglas A 2nd; McGuire SP; Kinnaman G; Hartwell JL; Maatman BT; Kreutz RP; Kapoor R; Rahman O; Zyromski NJ; Meagher AD; Critical care medicine 2020 May 27

IL-1R (Interleukin-1 Receptor) Signaling and Attenuated Hepatic CYP (Cytochrome P450) 2C Expression: Explanation for Higher Rate of Clopidogrel Resistance in Patients With Diabetes Mellitus?
Kreutz RP; Arteriosclerosis, thrombosis, and vascular biology 2020 May 27

Intensified P2Y12 inhibition for high-on treatment platelet reactivity.
Mshelbwala FS; Hugenberg DW; Kreutz RP; Journal of thrombosis and thrombolysis 2020 Mar 9

Personalizing Antithrombotic Therapy in COVID-19: Role of Thromboelastography and Thromboelastometry.
Chaudhary R; Kreutz RP; Bliden KP; Tantry US; Gurbel PA; Thrombosis and haemostasis 2020 Jul 17

Impact of Routine Platelet Reactivity Testing with VerifyNow Assay on Antiplatelet Choice After Percutaneous Coronary Intervention.
Mshelbwala FS; Hugenberg DW; Kreutz RP; Clinical pharmacology : advances and applications 2020 Apr 16

Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants.
Kanuri SH; Kreutz RP; Journal of personalized medicine 2019 Jan 17

Next generation MicroRNA sequencing to identify coronary artery disease patients at risk of recurrent myocardial infarction.
Kanuri SH; Ipe J; Kassab K; Gao H; Liu Y; Skaar TC; Kreutz RP; Atherosclerosis 2018 Oct 3

A comprehensive review and meta-analysis of risk factors for statin-induced myopathy.
Nguyen KA; Li L; Lu D; Yazdanparast A; Wang L; Kreutz RP; Whipple EC; Schleyer TK; European journal of clinical pharmacology 2018 May 22

Fibrin Clot Strength in Patients with Diabetes Mellitus Measured by Thrombelastography.
Maatman BT; Schmeisser G; Kreutz RP; Journal of diabetes research 2018 Feb 4

Prediction of Ischemic Events after Percutaneous Coronary Intervention: Thrombelastography Profiles and Factor XIIIa Activity.
Kreutz RP; Schmeisser G; Schaffter A; Kanuri S; Owens J; Maatman B; Sinha A; von der Lohe E; Breall JA; TH open : companion journal to thrombosis and haemostasis 2018 Apr

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA; IGNITE Network.; JACC. Cardiovascular interventions 2017 Oct 25

Common genetic polymorphisms of adenosine A2A receptor do not influence response to regadenoson.
Berlacher M; Mastouri R; Philips S; Skaar TC; Kreutz RP; Pharmacogenomics 2017 Mar 30

Multi-site investigation of strategies for the implementation of CYP2C19 genotype-guided antiplatelet therapy.
Empey PE; Stevenson JM; Tuteja S; Weitzel KW; Angiolillo DJ; Beitelshees AL; Coons JC; Duarte JD; Franchi F; Jeng LJB; Johnson JA; Kreutz RP; Limdi NA; Maloney KA; Owusu Obeng A; Peterson JF; Petry N; Pratt VM; Rollini F; Scott SA; Skaar TC; Vesely MR; Stouffer GA; Wilke RA; Cavallari LH; Lee CR; IGNITE Network.; Clinical pharmacology and therapeutics 2017 Dec 26

Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention.
Kreutz RP; Schmeisser G; Maatman B; Schaffter A; Sinha A; von der Lohe E; Breall JA; Thrombosis and haemostasis 2016 Nov 3

Implementation of a pharmacogenomics consult service to support the INGENIOUS trial.
Eadon MT; Desta Z; Levy KD; Decker BS; Pierson RC; Pratt VM; Callaghan JT; Rosenman MB; Carpenter JS; Holmes AM; McDonald CA; Benson EA; Patil AS; Vuppalanchi R; Gufford BT; Dave N; Robarge JD; Hyder MA; Haas DM; Kreutz RP; Dexter PR; Skaar TC; Flockhart DA; Clinical pharmacology and therapeutics 2016 Mar 31

Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention.
Kreutz RP; Breall JA; Sinha A; von der Lohe E; Kovacs RJ; Flockhart DA; Clinical pharmacology : advances and applications 2016 Jun 3

AMPD1 polymorphism and response to regadenoson.
Saab R; Zouk AN; Mastouri R; Skaar TC; Philips S; Kreutz RP; Pharmacogenomics 2015 Nov 10

Caffeine Consumption and Heart Rate and Blood Pressure Response to Regadenoson.
Bitar A; Mastouri R; Kreutz RP; PloS one 2015 Jun 22

Variations in Clinical Presentation, Risk Factors, Treatment, and Prognosis of Spontaneous Coronary Artery Dissection.
Sultan A; Kreutz RP; The Journal of invasive cardiology 2015 Aug

Platelet activation and pneumonia: is soluble p-selectin the right marker?
Gurbel PA; Kreutz RP; Bliden KP; Tantry US; Journal of the American College of Cardiology 2015 Apr 14

Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.
Kreutz RP; Bitar A; Owens J; Desta Z; Breall JA; von der Lohe E; Sinha A; Vatta M; Nystrom P; Jin Y; Flockhart DA; Journal of thrombosis and thrombolysis 2014 Oct

Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel.
Kreutz RP; Owens J; Lu D; Nystrom P; Jin Y; Kreutz Y; Desta Z; Flockhart DA; Platelets 2014 May 15

Amlodipine--not a significant contributor to clopidogrel non-response?
Kreutz RP; Flockhart DA; Heart (British Cardiac Society) 2013 Jan 12

Cytochrome P450 3A4*22, PPAR-a, and ARNT polymorphisms and clopidogrel response.
Kreutz RP; Owens J; Jin Y; Nystrom P; Desta Z; Kreutz Y; Breall JA; Li L; Chiang C; Kovacs RJ; Flockhart DA; Clinical pharmacology : advances and applications 2013 Dec 9

Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes.
Lu D; Owens J; Kreutz RP; Thrombosis research 2013 Aug 3

C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting.
Kreutz RP; Owens J; Breall JA; Lu D; von der Lohe E; Bolad I; Sinha A; Flockhart DA; Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2013 Apr

Spontaneous coronary artery dissection in a 14-year-old.
Cropp EM; Turner JS; Kreutz RP; The American journal of emergency medicine 2012 Nov 15

Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response.
Kreutz RP; Breall JA; Kreutz Y; Owens J; Lu D; Bolad I; von der Lohe E; Sinha A; Flockhart DA; Thrombosis research 2012 Mar 28

Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.
Kreutz RP; Nystrom P; Kreutz Y; Miao J; Kovacs R; Desta Z; Flockhart DA; Jin Y; Platelets 2012 Mar 2

Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response.
Kreutz RP; Nystrom P; Kreutz Y; Miao J; Desta Z; Breall JA; Li L; Chiang C; Kovacs R; Flockhart DA; Jin Y; Clinical pharmacology : advances and applications 2012 Feb 20

Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivity.
Kreutz RP; Alloosh M; Mansour K; Neeb Z; Kreutz Y; Flockhart DA; Sturek M; Diabetes, metabolic syndrome and obesity : targets and therapy 2011 Mar 15

Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study.
Kreutz RP; Stanek EJ; Aubert R; Yao J; Breall JA; Desta Z; Skaar TC; Teagarden JR; Frueh FW; Epstein RS; Flockhart DA; Pharmacotherapy 2010 Aug

Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study.
Tantry US; Bliden KP; Suarez TA; Kreutz RP; Dichiara J; Gurbel PA; Platelets 2010

The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting.
Gurbel PA; Bliden KP; Kreutz RP; Dichiara J; Antonino MJ; Tantry US; Platelets 2009 Mar

Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting.
Gurbel PA; Bliden KP; Cohen E; Navickas IA; Singla A; Antonino MJ; Fissha M; Kreutz RP; Bassi AK; Tantry US; Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2008 Jun

Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients.
Dichiara J; Bliden KP; Tantry US; Chaganti SK; Kreutz RP; Gesheff TB; Kreutz Y; Gurbel PA; Platelets 2007 Sep

Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression.
Gurbel PA; Kreutz RP; Bliden KP; DiChiara J; Tantry US; American heart journal 2007 Oct 17

Inflammatory changes during the 'common cold' are associated with platelet activation and increased reactivity of platelets to agonists.
Kreutz RP; Tantry US; Bliden KP; Gurbel PA; Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007 Dec

Viral respiratory tract infections increase platelet reactivity and activation: an explanation for the higher rates of myocardial infarction and stroke during viral illness.
Kreutz RP; Bliden KP; Tantry US; Gurbel PA; Journal of thrombosis and haemostasis : JTH 2005 Sep

Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.
Gurbel PA; Bliden KP; Guyer K; Cho PW; Zaman KA; Kreutz RP; Bassi AK; Tantry US; Journal of the American College of Cardiology 2005 Oct 21

Quantification of intact quadriceps tendon, quadriceps tendon insertion, and suprapatellar fat pad: MR arthrography, anatomy, and cryosections in the sagittal plane.
Staeubli HU; Bollmann C; Kreutz R; Becker W; Rauschning W; AJR. American journal of roentgenology 1999 Sep
Professional Organizations

American College of Cardiology

American Heart Association

Society for Cardiovascular Angiography and Interventions
Board Certifications

American Board of Internal Medicine - Cardiovascular Disease

American Board of Internal Medicine - Interventional Cardiology

American Board of Internal Medicine - Internal Medicine
Clinical Interests

Coronary artery disease, valvular heart disease, cardiac catheterization, coronary intervention, and transcatheter aortic valve replacement (TAVR).

Looking for patient care?

To schedule an appointment with a faculty member physician of IU School of Medicine, contact Indiana University Health at 888-484-3258 or use the physician finder by clicking the button below.

Find a doctor